PMID: 1061637Jan 1, 1976

Chromosomes and causation of human cancer and leukemia. XI. Correlation of karyotypes with clinical features of acute myeloblastic leukemia

Cancer
M Sakurai, A A Sandberg

Abstract

Acute myeloblastic leukemia (AML) patients with chromosomal abnormalities in their bone marrow cells were divided into those with minor karyotypic abnormalities (MIKA) and those with major karyotypic abnormalities (MAKA). One of the largest subgroups in the MIKA group was shown to have cytologic characteristics typical of so-called "classical" AML and a "prototypic" karyotype, which has been shown to be due to translocation between chromosomes number 8 and number 21. A missing Y chromosome in AML was mostly associated with this karyotype. Patients of the MAKA group were usually erythroleukemic, had no or very few normal metaphases among the abnormal ones in the marrow, and almost invariably showed karyotypic instability. Karyotypic differences did not affect the patients' survival after the initiation of chemotherapy as much as did the presence or absence of normal metaphases. However, the karyotypes do appear to be relevant to the decision as to whether a patient should be administered chemotherapy when no normal metaphases are found on the initial bone marrow examination.

References

Feb 17, 1973·Lancet·A A Sandberg, M Sakurai
Dec 8, 1973·Lancet·P PetitP Fondu
Mar 1, 1974·British Journal of Haematology·F J RuttenD J Wagener
Jan 1, 1973·Journal of the National Cancer Institute·F W GunzP C Vincent
Oct 1, 1973·American Journal of Clinical Pathology·L F MeisnerT W Chuprevich
Dec 1, 1972·Journal of Medical Genetics·H Van Den BergheH Verresen
Feb 1, 1974·The Journal of Pediatrics·L G MacdougallJ M Judisch
Nov 1, 1965·Cancer·C W Heath, W C Moloney
Aug 1, 1966·Acta Medica Scandinavica·M K Jensen
Apr 1, 1968·Cancer·L S GoldbergR S Sparkes
Mar 1, 1969·Journal of Medical Genetics·P E CrossenL A Brehaut
Dec 1, 1969·Annals of Internal Medicine·E Z EzdinliA A Sandberg
Nov 1, 1969·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A Forni, L Moreo
Jul 1, 1970·Blut·M H Khan, H Martin
Sep 1, 1971·Annals of Internal Medicine·J S HartE Frei
Nov 1, 1971·Acta Medica Scandinavica·M K Jensen
Feb 28, 1964·Annals of the New York Academy of Sciences·P C NOWELL, D A HUNGERFORD
Jan 1, 1960·British Journal of Haematology·D QUAGLINO, F G Hayhoe

Citations

Jan 1, 1979·Human Genetics·E L PrigoginaI S Peterson
May 1, 1980·Pediatric Clinics of North America·N L KobrinskyM E Nesbit
Aug 1, 1981·Cancer Genetics and Cytogenetics·R Berger
Nov 1, 1981·Cancer Genetics and Cytogenetics·F MitelmanB Dallapiccola
Dec 1, 1981·Cancer Genetics and Cytogenetics·J TakeuchiI Amaki
Dec 1, 1981·Cancer Genetics and Cytogenetics·M SessaregoF Ajmar
Mar 1, 1981·Cancer Genetics and Cytogenetics·A HagemeijerJ Abels
Mar 1, 1981·Cancer Genetics and Cytogenetics·D L Van DykeM Poel
Oct 1, 1982·Cancer Genetics and Cytogenetics·P BernardA Broustet
Aug 1, 1983·Cancer Genetics and Cytogenetics·R MorganF Hecht
Mar 1, 1983·Cancer Genetics and Cytogenetics·E C Douglass, D L Freeman
Feb 1, 1984·Cancer Genetics and Cytogenetics·C M Morris, P H Fitzgerald
Mar 15, 1985·Cancer Genetics and Cytogenetics·J BenítezH Heimpel
Dec 1, 1985·Cancer Genetics and Cytogenetics·G Juliusson, G Gahrton
Jan 1, 1986·Cancer Genetics and Cytogenetics·S R Wolman
Feb 1, 1987·Cancer Genetics and Cytogenetics·P H FitzgeraldP E Hollings
Aug 1, 1988·Cancer Genetics and Cytogenetics·R BergerA Bernheim
Apr 1, 1990·Cancer Genetics and Cytogenetics·G Juliusson, G Gahrton
Jul 1, 1991·Cancer Genetics and Cytogenetics·A L HawkinsC A Griffin
Mar 1, 1992·Cancer Genetics and Cytogenetics·G PalkaG Torlontano
Feb 1, 1996·Cancer Genetics and Cytogenetics·N HdaA Benslimane
Aug 28, 1980·The New England Journal of Medicine·H J WeinsteinE Frei
Jul 16, 1981·The New England Journal of Medicine·J D Rowley
Jan 1, 1978·British Journal of Haematology·D Francesconi, F Pasquali
May 17, 2014·Human Molecular Genetics·A RafiiJ A Malek
Dec 15, 1977·International Journal of Cancer. Journal International Du Cancer·J D RowleyD Potter
Jun 1, 1978·Clinics in Haematology·J D Rowley
Dec 1, 1978·The Journal of Pediatrics·Y KanekoM Hattori
Sep 1, 1983·Cancer Treatment Reviews·J S Hart
Aug 1, 1983·Current Problems in Cancer·A A Sandberg
Mar 1, 1980·British Journal of Haematology·S D LawlerT J McElwain
Apr 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Levi A Garraway
Dec 1, 1987·Cancer·J Stamberg
Dec 1, 1979·Cancer·M F van der Riet-FoxW A van Niekerk
Apr 1, 1979·Clinical Genetics·V M Riccardi, J Forgason
Apr 1, 1984·Scandinavian Journal of Haematology·A GustavssonI Olsson
Aug 16, 1976·European Journal of Pediatrics·H Müller, G R Stalder
Mar 1, 1988·European Journal of Haematology·R BillströmF Mitelman
Mar 14, 1998·American Journal of Clinical Oncology·S L GoldbergG W Dewald
Jul 1, 1986·Scandinavian Journal of Haematology·R BillströmF Mitelman

Related Concepts

Antineoplastic Agents
Marrow
Bone Marrow Cells
Autosome Abnormalities
Partial Monosomy
Acute Erythroblastic Leukemia
Karyotype Determination Procedure
M Phase, Mitotic
Chromosomal Translocation
Acute Myeloid Leukemia, M1

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.